UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER ~~PURSUANT TO RULE 13a-16~~

ORPURSUANT ~~15d~~TO RULE 13a-16 ~~UNDER~~OR ~~THE SECURITIES EXCHANGE ACT OF 1934~~ 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2025

Commission File Number: 001-42450

Zhengye Biotechnology Holding Limited

No.1 Lianmeng Road, Jilin Economic & Technical Development Zone Jilin City, Jilin Province, China

Jilin City, Jilin Province, China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.:

Form 20-F ☒ Form 40-F ☐

On January 813, 2025, ~~Zhengye~~Kingswood ~~Biotechnology~~Capital ~~Holding~~Partners, ~~Limited~~LLC (~~the~~ “~~Company~~Kingswood”), ~~closed~~as ~~its~~the ~~initial~~representative ~~public~~of ~~offering~~the ~~(“IPO”)~~ underwriters of ~~1,500,000~~the ~~ordinary~~initial public ~~shares,~~offering ~~par~~of ~~value~~Zhengye ~~$0.000025~~Biotechnology ~~per~~Holding ~~share~~Limited (the “~~Ordinary Shares~~Company”)., ~~The~~exercised ~~Company~~its ~~completed~~over-allotment ~~the~~option ~~IPO pursuant~~in full to purchase ~~its~~an ~~registration~~additional ~~statement~~225,000 onordinary ~~Form~~shares ~~F-1~~of ~~(File~~the ~~No.~~Company ~~333-276436),~~at ~~which~~the ~~was~~public ~~initially~~offering ~~filed~~price ~~with~~of ~~the U~~US$4.S.00 ~~Securities~~per ~~and~~share ~~Exchange Commission~~ (the “~~SEC~~Option”). The onclosing ~~January~~for 9,the ~~2024,~~sale asof ~~amended,~~the ~~and~~over-allotment ~~declared~~shares ~~effective~~took byplace ~~the SEC~~ on ~~December~~January 2014, ~~2024~~2025. ~~The Ordinary~~ ~~Shares~~As ~~were~~a ~~priced at $4.00 per share~~result, ~~and~~ the ~~offering~~gross ~~was~~proceeds ~~conducted~~of onthe ~~a firm commitment basis. The Ordinary Shares~~Company’s ~~were~~initial ~~previously~~public ~~approved~~offering, ~~for~~including ~~listing~~the onproceeds ~~The~~from ~~Nasdaq~~the ~~Capital~~sale ~~Market~~of ~~and~~the ~~commenced~~over-allotment ~~trading~~shares, ~~under~~totaled ~~the~~US$6,900,000, ~~ticker~~before ~~symbol~~deducting ~~“ZYBT” on~~underwriting ~~January~~discounts 7,and ~~2025~~other related expenses.

InA ~~connection~~copy ~~with~~of the ~~IPO,~~press release announcing the ~~Company~~underwriters’ ~~entered~~exercise ~~into~~of anthe ~~underwriting~~Option ~~agreement,~~is ~~dated~~attached ~~January~~as 6,Exhibit ~~2025~~99.1 ~~(the~~and ~~“Underwriting~~incorporated ~~Agreement”),~~herein ~~with~~by ~~Kingswood~~reference. ~~Capital~~This ~~Partners,~~report ~~LLC~~does ~~(the~~not ~~“Representative”)~~constitute an offer to sell, aor ~~copy~~the solicitation of ~~which~~an isoffer ~~attached~~to ~~hereto~~buy, asnor ~~Exhibit~~shall ~~10.1~~there ~~and~~be ~~incorporated~~any sale of ~~herein~~these bysecurities ~~reference.~~in ~~The~~any ~~foregoing~~state ~~summaries~~or ofjurisdiction ~~the~~in ~~Underwriting~~which ~~Agreement~~such ~~are~~offer, ~~subject~~solicitation, or sale would be unlawful prior to, ~~and~~the ~~qualified~~registration or inqualification ~~their~~under ~~entirety~~the ~~by,~~securities laws of any such ~~document~~state or jurisdiction.

InEXHIBIT connection with the IPO, the Company issued a press release on January 6, 2025, announcing the pricing of the IPO, and a press release on January 8, 2025, announcing the closing of the IPO, respectively. Copies of the two press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference herein.INDEX

This report does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Exhibit No.		Description
99.1		Press Release dated January 14, 2025, announcing the exercise of the over-allotment option.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Zhengye Biotechnology Holding Limited By: /s/ Songlin Song Name: Songlin Song Title: Chief Executive Officer

	Zhengye Biotechnology Holding Limited

Date: January 14, 2025	By:	/s/ Songlin Song
	Name:	Songlin Song
	Title:	Chief Executive Officer

Date: January 8, 2025

EXHIBIT INDEX

Exhibit No.		Description
10.1		Underwriting Agreement dated January 6, 2025, by and between the Company and Representative
99.1		Press Release dated January 6, 2025, announcing the pricing of the IPO
99.2		Press Release dated January 8, 2025, announcing the closing of the IPO

Filing Compare · Zhengye Biotechnology Holding Ltd